SNPMiner Trials (Home Page)
Report for SNP rs2601126
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial
The use of Kava in Generalised Anxiety Disorder: an 18-week double-blind, randomised, placebo-controlled study.
NCT02219880 Generalized Anxiety Disorder Dietary Supplement: Kava (240mg of kavalactones per day) Dietary Supplement: Placebo MeSH:Disease Anxiety Disorders
Specifically, whether rs2601126-T allele or rs2697153-A allele carriers have greater reduction of anxiety.
Primary Outcomes
Description: Reduction of participant's anxiety will be assessed on the HAMA from baseline to week 16 across time used a mixed methods model.
Measure: Hamilton Anxiety Rating Scale (HAMA) - change in score Time: 18 weeksSecondary Outcomes
Description: Will assess whether response to Kava will be moderated by gamma-aminobutyric acid (GABA) transporter polymorphisms. Specifically, whether rs2601126-T allele or rs2697153-A allele carriers have greater reduction of anxiety
Measure: Gamma-aminobutyric acid (GABA) transporter polymorphisms moderating response to study intervention Time: 18 weeksOther Outcomes
Description: Depressive symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS), self-rated anxiety on the Beck Anxiety Inventory (BAI), pathological worry on the Penn State Worry Questionnaire (PSWQ), and health-related quality of life on the Short Form Survey-12 (SF-12) will also be significantly improved by Kava over placebo; and
Measure: Changes in score to psychometric questionnaire measures Time: 18 weeksDescription: Differential gene expression will be assessed from baseline to week 8 from participants in the Melbourne site. This will determine whether Kava increases expression of genes effecting expression of neurochemical e.g. GABA, and monoamines
Measure: Monoamine and GABA differential gene expression Time: 8 weeks